A study on assessment of inappropriate prescribing of proton pump inhibitors at a teaching hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20254156Keywords:
Proton pump inhibitors, Appropriateness, NICE guidelines, Prophylaxis, Concomitant useAbstract
Background: Proton pump inhibitors (PPI’s) are amongst the most extensively utilized therapies for conditions characterized by excessive gastric-acid production, making them highly susceptible to inappropriate long-term use predisposing individuals to a higher risk of side effects. This study seeks to evaluate the prevalence and patterns of inappropriate PPI prescribing in both in-patients and out-patients, with a focus on adherence to clinical guidelines regarding indications, dosage, frequency, and duration of therapy by using National Institute for Health and Care Excellence (NICE) guidelines.
Methods: Appropriateness of PPI prescriptions was prospectively assessed in 120 in-patients during their hospitalization and at discharge, and 50 out-patients with regard to the indication, dosage, frequency and duration of therapy for their compliance with NICE guidelines. The required data for the study was noted in a suitably designed data collection form.
Results: Among 120 in-patients, 56 (46.67%) were males and 64 (53.33%) were females. Pantoprazole 40 mg was the commonly prescribed PPI, accounting 115 (95.83%) IV and 5 (4.17%) oral prescriptions among In-patients whereas 94 (93.07%) prescriptions account for pantoprazole 40 mg and 7 (6.93%) with rabeprazole 20 mg during discharge, all through an oral route. On assessing the appropriateness of prescription, it was revealed that 80 (66.67%) were appropriate, while 40 (33.33%) were inappropriate in IPD. In 35 inappropriate indications, 14 (40%) are due to prophylaxis in low-risk patients with concomitant use of NSAIDs and 1 (2.86%) with corticosteroids. Twenty (57.15%) prescriptions had no indications. Four (10%) prescriptions had inappropriate frequency and 1 (2.50%) had inappropriate duration. Among the out-patients, 32 (64%) were males and 18 (36%) females. Pantoprazole 40 mg was prescribed in 5 (10%) through an IV route and 32 (64%) were oral prescriptions whereas 13 (26%) were given rabeprazole 20 mg orally. Inappropriateness was seen in 14 (77.78%) due to prophylaxis in low-risk patients co-prescribed with NSAIDs and 4 (22.22%) prescriptions had no clear indications. Three (14.29%) accounted for inappropriate frequency.
Conclusions: The study concludes that, the rate of inappropriate prescribing of PPIs is relatively low in both in-patients during hospitalization, at discharge, and in outpatients. Pharmacists can work closely with prescribers to ensure the proper indication, dose, frequency and duration of therapy.
Metrics
References
Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008;68(7):925-47. DOI: https://doi.org/10.2165/00003495-200868070-00004
Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motility. 2013;19(1):25. DOI: https://doi.org/10.5056/jnm.2013.19.1.25
Yu LY, Sun LN, Zhang XH, Li YQ, Yu L, Yuan ZQ, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34(5):1070-86. DOI: https://doi.org/10.1007/s12325-017-0532-9
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. J Am College Gastroenterol| ACG. 2013;108(3):308-28. DOI: https://doi.org/10.1038/ajg.2012.444
Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid- related disorders. Drugs. 1992;44(2):225-50. DOI: https://doi.org/10.2165/00003495-199244020-00007
Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Die Pharmazie. 2002;57(9):595-601.
Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther. 2000;22(11):1268-93. DOI: https://doi.org/10.1016/S0149-2918(00)83025-8
Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinetics. 2001;40(6):411-26. DOI: https://doi.org/10.2165/00003088-200140060-00003
Wittbrodt ET, Baum C, Peura DA. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin and Exp Gastroenterol. 2009:117-28. DOI: https://doi.org/10.2147/CEG.S5765
Shung DL, Laine L. Upper gastrointestinal bleeding–review of current evidence and implications for management. Aliment Pharmacol Ther. 2024;59(9):1062-81. DOI: https://doi.org/10.1111/apt.17949
Gupta Y, Bhandari S, Govil A, Gupta R, Goyal J, Goyal B, et al. Use and inappropriate use of proton pump inhibitors in hospitalized patients. Intl J Basic Clin Pharmacol. 2019;8(11):2490. DOI: https://doi.org/10.18203/2319-2003.ijbcp20194790
Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, et al. Appropriateness of proton pump inhibitors treatment in clinical practice: prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liv Dis. 2020;52(8):862-8. DOI: https://doi.org/10.1016/j.dld.2020.05.005
Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol. 2011;4(2):53-9. DOI: https://doi.org/10.1007/s12328-011-0208-y
Kunwar N, Kumaraswamy M, Shrestha S, Paudel S, Kafle B, Pokharel T, et al. A study on proton pump inhibitors in the general medicine unit of a tertiary care teaching hospital. World J Pharm Res. 2015;4(6):1519-34
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2-3. DOI: https://doi.org/10.1136/bmj.39406.449456.BE
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-42. DOI: https://doi.org/10.1001/jama.2013.280490
Dyspepsia and gastro-oesophageal reflux disease: investigation and management. NICE Clinical Guideline [CG184]. 2014.
Atkins AM, Sekar MC, Ph R. Proton pump inhibitors: Their misuse, overuse and abuse. IOSR J Pharm. 2013;3(2):25-9. DOI: https://doi.org/10.9790/3013-32202529
Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm and Ther. 2000;25(5):333-40. DOI: https://doi.org/10.1046/j.1365-2710.2000.00312.x
Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189-93. DOI: https://doi.org/10.1007/s11096-006-9028-4
Juneja S, Rana P, Manoj SV, Kalia R, Singh RP. Appropriateness of Proton Pump Inhibitor Use in Hospitalized Patients: A Cross-Sectional Study in a Tertiary Care Hospital in North India. J Pharm Care 2023;11(2):61-5. DOI: https://doi.org/10.18502/jpc.v11i2.13360
Verma N, Tayal V, Roy V. Proton pump inhibitors: prescribing practices, appropriateness of use, and cost incurred in a tertiary care, public, teaching hospital in New Delhi, India. MAMC J Med Sci. 2019;5(3):113-20. DOI: https://doi.org/10.4103/mamcjms.mamcjms_40_19
Damji SS, Rabbani SA, Rao PG, Butt AU. Proton pump inhibitor use and appropriateness analysis: a snapshot from a secondary care hospital. J Pharm Health Services Res. 2021;12(2):206-12. DOI: https://doi.org/10.1093/jphsr/rmab013
Mat Saad AZ, Collins N, Lobo MM, O'connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish General Hospital. Intl J Clin Pract. 2005;59(1):31-4. DOI: https://doi.org/10.1111/j.1742-1241.2004.00298.x
Marie I, Moutot A, Tharrasse A, Hellot MF, Robaday S, Hervé F, et al. Validity of proton pump inhibitors' prescriptions in a department of internal medicine. La Revue de Med Interne. 2006;28(2):86-93. DOI: https://doi.org/10.1016/j.revmed.2006.09.030
Basyal B, Marasine NR, Sankhi S, Lamichhane R, Uprety BN. Prescribing pattern of proton pump inhibitors among patients visiting the outpatient general medicine clinic in a tertiary care teaching hospital in Nepal. J Health Res. 2022;36(5):946-53. DOI: https://doi.org/10.1108/JHR-09-2020-0420
Awanish K, Gyan BR, Ashish KS, Vandana K. How appropriately are adults being prescribed proton pump inhibitors-experience of a tertiary care centre. Intl J Health Clin Res. 2021;4(7):238-41.
Downloads
Published
How to Cite
Issue
Section
